180 Life Sciences (180 Life Sciences) EBIT per Share : $-47.34 (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences EBIT per Share?

180 Life Sciences's EBIT per Share for the three months ended in Mar. 2024 was $-1.65. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-47.34.

During the past 3 years, the average EBIT per Share Growth Rate was 32.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for 180 Life Sciences's EBIT per Share or its related term are showing as below:

ATNF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 32.9 Med: 35 Max: 37.1
Current: 32.9

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of 180 Life Sciences was 37.10% per year. The lowest was 32.90% per year. And the median was 35.00% per year.

ATNF's 3-Year EBIT Growth Rate is ranked better than
82.99% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs ATNF: 32.90

180 Life Sciences's EBIT for the three months ended in Mar. 2024 was $-1.05 Mil.

180 Life Sciences EBIT per Share Historical Data

The historical data trend for 180 Life Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences EBIT per Share Chart

180 Life Sciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-869.59

-204.54

-242.92

-396.41

-58.68

180 Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-24.12	-13.34	-30.07	-2.28	-1.65

180 Life Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

180 Life Sciences's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.24	/	0.379
=	-58.68

180 Life Sciences's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.053	/	0.638
=	-1.65

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.34

180 Life Sciences (NAS:ATNF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

180 Life Sciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

180 Life Sciences (180 Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306

Website

https://www.180lifesciences.com

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.

Executives

James N. Woody	director, officer: Chief Executive Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann	director	5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A.	director	C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu	officer: COO / Chief Business Officer	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir	officer: Interim CFO	2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone	director	C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca	director	40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis	director	205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss	director, 10 percent owner, officer: Chief Executive Officer	C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold	director	830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard	officer: Chief Scientific Officer	501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker	director	290 COMMONWEALTH AVENUE #17, BOSTON MA 02115